Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation

Leukemia volume 29, pages 1390–1401 (2015)Cite this article

Subjects

Abstract

Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, we developed a human patient-derived tumorgraft (hPDT) line. Molecular characterization of primary and PDT cells demonstrated the activation of ALK and nuclear factor kB (NFkB) pathways. Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells, lacking PRDM1/Blimp1 and carrying c-MYC gene amplification. The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. Moreover, a NFkB gene set classifier stratified ALCL in distinct subsets with different clinical outcome. Although a selective ALK inhibitor (CEP28122) resulted in a significant clinical response of hPDT mice, nevertheless the disease could not be eradicated. These data indicate that the activation of NFkB signaling contributes to the neoplastic phenotype of TRAF1-ALK ALCL. ALCL hPDTs are invaluable tools to validate the role of druggable molecules, predict therapeutic responses and implement patient specific therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. Falini B, Martelli MP . Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica 2009; 94: 897–900.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Swerdlow SH CE, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW . WHO classification of tumors of haemotolopoietic and lymphoid tissues, 4th edn. Stylus Publishing, LLC: Sterling VA, 2008.

    Google Scholar 

  3. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504.

    Article  CAS  PubMed  Google Scholar 

  4. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418–3425.

    Article  CAS  PubMed  Google Scholar 

  5. Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J et al. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol 2007; 82: 59–64.

    Article  PubMed  Google Scholar 

  6. Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L et al. Dual ALK and MYC Rearrangements Leading to an Aggressive Variant of Anaplastic Large Cell Lymphoma. J Pediatr Oncol 2013; 35: e209–e213.

    Article  Google Scholar 

  7. Ferreri AJ, Govi S, Pileri SA, Savage KJ . Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncology Hematol 2012; 83: 293–302.

    Article  Google Scholar 

  8. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011; 47: R11–R23.

    Article  CAS  PubMed  Google Scholar 

  9. Miranda C, Roccato E, Raho G, Pagliardini S, Pierotti MA, Greco A . The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway. J Cell Physiol 2006; 208: 154–160.

    Article  CAS  PubMed  Google Scholar 

  10. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbo F et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood 2013; 122: 2683–2693.

    Article  CAS  PubMed  Google Scholar 

  11. Grewal JS, Smith LB, Winegarden JD 3rd, Krauss JC, Tworek JA, Schnitzer B . Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol 2007; 86: 499–508.

    Article  PubMed  Google Scholar 

  12. Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H . C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC. Am J Hematol 2011; 86: 75–78.

    Article  CAS  PubMed  Google Scholar 

  13. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL . Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012; 12: 786–798.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ . Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593–598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338–350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Garber K . From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101: 6–8.

    Article  PubMed  Google Scholar 

  17. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Martino Rodriguez A et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012; 26: 1517–1526.

    Article  CAS  PubMed  Google Scholar 

  18. Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2011; 11: 670–679.

    Article  PubMed  Google Scholar 

  19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Res 2006; 12: 4652–4661.

    Article  CAS  Google Scholar 

  20. Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, Eckloff BW et al. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer 2013; 52: 1097–1102.

    Article  CAS  PubMed  Google Scholar 

  21. Tabbo F, Barreca A, Machiorlatti R, Messana K, Landra I, Abate F et al. Humanized NOD/Scid/IL2g−/− tumor grafts recapitulate primary anaplastic large cell lymphoma. AACR Annual Meeting 2013 2013; (abstract 3853).

  22. Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010; 28: 1583–1590.

    Article  CAS  PubMed  Google Scholar 

  23. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014; 46: 166–170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Abate F, Acquaviva A, Paciello G, Foti C, Ficarra E, Ferrarini A et al. Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. Bioinformatics 2012; 28: 2114–2121.

    Article  CAS  PubMed  Google Scholar 

  25. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Iyer MK, Chinnaiyan AM, Maher C . ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903–2904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231–1235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95: 2144–2149.

    CAS  PubMed  Google Scholar 

  29. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 2012; 120: 1274–1281.

    Article  CAS  PubMed  Google Scholar 

  30. Shultz LD, Ishikawa F, Greiner DL . Humanized mice in translational biomedical research. Nat Rev Immunology 2007; 7: 118–130.

    Article  CAS  PubMed  Google Scholar 

  31. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98: 953–963.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038–1047.

    Article  CAS  PubMed  Google Scholar 

  33. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006; 107: 689–697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L et al. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 2009; 113: 2776–2790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Fu L, Medico E . FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics 2007; 8: 3.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123: 2915–2923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP . GenePattern 2.0. Nat Genet 2006; 38: 500–501.

    Article  CAS  PubMed  Google Scholar 

  38. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Nat l Acad Sci USA 2005; 102: 15545–15550.

    Article  CAS  Google Scholar 

  39. Jiang C, Xuan Z, Zhao F, Zhang MQ . TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res 2007; 35: D137–D140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392–1399.

    Article  CAS  PubMed  Google Scholar 

  41. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell 2011; 43: 798–810.

    Article  CAS  PubMed  Google Scholar 

  42. Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol 2010; 184: 3570–3581.

    Article  CAS  PubMed  Google Scholar 

  43. Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F et al. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol 2013; 162: 566–569.

    Article  CAS  PubMed  Google Scholar 

  44. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 354–362.

    Article  CAS  PubMed  Google Scholar 

  45. Tabbo F, Barreca A, Piva R, Inghirami G . ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol 2012; 2: 41.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell 2004; 5: 353–364.

    Article  CAS  PubMed  Google Scholar 

  47. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046–1052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717–721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Eng J Med 2008; 359: 2313–2323.

    Article  CAS  Google Scholar 

  50. Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB et al. The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol 2013; 183: 1971–1980.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254–2263.

    Article  CAS  PubMed  Google Scholar 

  52. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340–4347.

    CAS  PubMed  Google Scholar 

  53. Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005; 106: 4287–4293.

    Article  CAS  PubMed  Google Scholar 

  54. Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009; 23: 2129–2138.

    Article  CAS  PubMed  Google Scholar 

  55. Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009; 113: 4894–4902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007; 21: 1521–1531.

    Article  CAS  PubMed  Google Scholar 

  57. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med 2012; 18: 1699–1704.

    Article  CAS  PubMed  Google Scholar 

  58. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120: 2280–2289.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208: 653–661.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

GI is supported by the Italian Association for Cancer Research Special Program in Clinical Molecular Oncology, Milan (5 × 1000 No. 10007); Regione Piemonte (ONCOPROT, CIPE 25/2005); ImmOnc (Innovative approaches to boost the immune responses, Programma Operativo Regionale, Piattaforme Innovative BIO FESR 2007/13, Asse 1 ‘Ricerca e innovazione’ della LR 34/2004) and the Oncology Program of Compagnia di San Paolo, Torino. SP and BF are supported by the Italian Association for Cancer Research Special Program in Clinical Molecular Oncology, Milan (5x1000 No. 10007); RR by Partnership for Cure, NIH 1 P50 MH094267-01, NIH 1 U54 CA121852-05, NIH 1R01CA164152-01. FB is sponsored by the Oncosuisse KLS-02403-02-2009 (Bern, Switzerland); Anna Lisa Stiftung (Ascona, Switzerland); Nelia and Amadeo Barletta Foundation (Lausanne, Switzerland); RP by Rete Oncologica del Piemonte e della Valle d’Aosta. LDS is sponsored by National Institutes of Health (USA) grant CA034196. MB, MT, IL, FT FDG, RC and LB are enrolled in the PhD program (Pharmaceutical Sciences, University of Geneva, Switzerland and Molecular Medicine, University of Torino, respectively). We thank Drs Vigliani C, Fioravanti A and Mossino M for their technical support and Dr Casano J for the constructive revision of the manuscript.

Author information

Author notes

  1. M Cheng

    Present address: 22Current addresses: In Vitro Pharmacology, Merck Research Laboratory, BMB11-138, 33 Avenue Louis Pasteur, Boston, MA 02115.,

  2. F Abate, M Todaro and J-A van der Krogt: These authors contributed equally to this work.

  3. See Appendix.

Authors and Affiliations

  1. Department of Control and Computer Engineering, Politecnico di Torino, Turin, Italy

    F Abate, E Ficarra, A Acquaviva & R Piva

  2. Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA

    F Abate & R Rabadan

  3. Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Turin, Italy

    F Abate, M Todaro, M Boi, I Landra, R Machiorlatti, F Tabbò, K Messana, C Abele, A Barreca, D Novero, M Gaudiano, S Aliberti, F Di Giacomo, E Lasorsa, R Crescenzo, L Bessone & G Inghirami

  4. Department of Human Genetics, KU Leuven, Leuven, Belgium

    J-A van der Krogt & I Wlodarska

  5. Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland

    M Boi, A Rinaldi, I Kwee & F Bertoni

  6. Department of Pathology, Translational Cell and Tissue Research, KU Leuven, UZ Leuven, Leuven, Belgium

    T Tousseyn

  7. Pathology & Lymphoid Malignancies Units, San Raffaele Scientific Institute, Milan, Italy

    M Ponzoni

  8. Department of Chemistry IFM and Molecular Imaging Center, Molecular Imaging Center, University of Torino, Turin, Italy

    D L Longo & S Aime

  9. Teva Pharmaceuticals, Inc, North Wales, PA, USA

    M Cheng & B Ruggeri

  10. Institute of Hematology and Medical Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

    P P Piccaluga & S Pileri

  11. Institute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, Italy

    E Tiacci & B Falini

  12. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

    B Pera-Gresely & L Cerchietti

  13. The Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA

    J Iqbal

  14. Department of Pathology, City of Hope Medical Center, Duarte, CA, USA

    W C Chan

  15. The Jackson Laboratory, Bar Harbor, ME, USA

    L D Shultz

  16. IDSIA Dalle Molle Institute for Artificial Intelligence, Manno, Switzerland

    I Kwee

  17. SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

    I Kwee

  18. Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA

    R Piva & G Inghirami

  19. Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

    F Bertoni

  20. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

    G Inghirami

Authors
  1. F Abate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Todaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-A van der Krogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Boi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Landra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Machiorlatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Tabbò
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Messana
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Abele
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Barreca
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Novero
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Gaudiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Aliberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Di Giacomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. T Tousseyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E Lasorsa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R Crescenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. L Bessone
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. E Ficarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Acquaviva
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. A Rinaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. M Ponzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. D L Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. S Aime
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. M Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. B Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. P P Piccaluga
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. S Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. E Tiacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. B Falini
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. B Pera-Gresely
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. L Cerchietti
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. J Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. W C Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. L D Shultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. I Kwee
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. R Piva
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. I Wlodarska
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. R Rabadan
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. F Bertoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. G Inghirami
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The European T-cell Lymphoma Study Group

Corresponding authors

Correspondence to R Rabadan, F Bertoni or G Inghirami.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Appendix

Appendix

Appendix The European T-Cell Lymphoma Study Group:

Italy: Cristina Abele, Luca Bessone, Antonella Barreca, Michela Boi, Federica Cavallo, Nicoletta Chiesa, Ramona Crescenzo, Antonella Fienga, Marcello Gaudiano, Filomena di Giacomo, Giorgio Inghirami, Indira Landra, Elena Lasorsa, Rodolfo Marchiorlatti, Barbara Martinoglio, Enzo Medico, Gian Battista Ferrero, Katia Messana, Elisabetta Mereu, Elisa Pellegrino, Roberto Piva, Irene Scafò, Elisa Spaccarotella, Fabrizio Tabbò, Maria Todaro, Ivana Ubezzi, Susanna Urigu (Azienda Ospedaliera Città della Salute e della Scienza di Torino, University of and Center for Experimental Research and Medical Studies); Domenico Novero, Annalisa Chiapella and Umberto Vitolo (Azienda Ospedaliera Città della Salute e della Scienza di Torino and San Luigi Gonzaga, Turin); Francesco Abate, Elisa Ficarra, Andrea Acquaviva (Politecnico di Torino); Luca Agnelli and Antonino Neri (University of Milan); Anna Caliò Marco Chilosi and Alberto Zamó (University of Verona); Fabio Facchetti and Silvia Lonardi (University of Brescia); Anna De Chiara and Franco Fulciniti (National Cancer Institute, Naples); Andrés Ferreri and Maurilio Ponzoni (San Raffaele Institute, Milan); Claudio Agostinelli, Pier Paolo Piccaluga and Stefano Pileri (University of Bologna); Brunangelo Falini and Enrico Tiacci (University of Perugia). Belgium: Peter Van Loo, Thomas Tousseyn, and Christiane De Wolf-Peeters (University of Leuven); Germany: Eva Geissinger, Hans Konrad Muller-Hermelink and Andreas Rosenwald, (University of Wuerzburg); Spain: Miguel Angel Piris and Maria E. Rodriguez (Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander and Instituto de Investigaciones Biomédicas Alberto Sols, CSIC-UAM, Madrid); Switzerland: Francesco Bertoni, Andrea Rinaldi, Ivo Kwee (Institute of Oncology Research, Bellizona). Brasil: Carlos Chiattone (Disciplina de Hematologia e Oncologia, FCM da Santa Casa de São Paulo) and Roberto Antonio Pinto Paes (Department of Pathology FCM da Santa Casa de São Paulo).

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abate, F., Todaro, M., van der Krogt, JA. et al. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia 29, 1390–1401 (2015). https://doi.org/10.1038/leu.2014.347

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.347

This article is cited by

Search

Advanced search

Quick links